Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition.
Verginelli F, Pisacane A, Gambardella G, D'Ambrosio A, Candiello E, Ferrio M, Panero M, Casorzo L, Benvenuti S, Cascardi E, Senetta R, Geuna E, Ballabio A, Montemurro F, Sapino A, Comoglio PM, Boccaccio C. Verginelli F, et al. Among authors: sapino a. Nat Commun. 2021 May 3;12(1):2498. doi: 10.1038/s41467-021-22643-w. Nat Commun. 2021. PMID: 33941777 Free PMC article.
[Standardized pathological reporting for tumors].
Abbona GC, Papotti M, Montemurro F, Viberti L, Sapino A, Bussolati G. Abbona GC, et al. Among authors: sapino a. Pathologica. 1997 Oct;89(5):546-65. Pathologica. 1997. PMID: 9489404 Italian. No abstract available.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Among authors: sapino a. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. Bertotti A, et al. Among authors: sapino a. Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. Cancer Discov. 2011. PMID: 22586653 Free article.
400 results